Genitourinary Cancers

The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by December 29, 2024.

Acceptance of the IND application would initiate a first-in-human phase 1 dose expansion and escalation trial of CTIM-76 in patients with testicular and gynecologic cancers.

“This data should bolster physicians’ confidence in recommending active surveillance for their patients when it is an appropriate option," says Timothy J. Daskivich, MD.

Preliminary data showed that the treatment was well-tolerated, and a maximum tolerated dose had not yet been reached.

Those who experienced a response with neoadjuvant chemotherapy had a median overall survival of 73.0 months, compared with 17.0 months among non-responders.

Overall, 39.1% of patients with malignant ureteral obstruction were referred to palliative care over the study period.

The positioning system would allow patients with cancer to undergo radiation therapy in an upright, seated position.

About 1 of every 5 patients with stage I seminoma relapses; however, “the level of evidence supporting the use of currently defined risk factors in decision making is low,” wrote lead author Thomas Wagner, MD, and coinvestigators.

“Our findings show that AI chatbots provided accurate information with little misinformation. However, the information was provided at a college reading level and with little actionability," says Abdo E. Kabarriti, MD, FACS.

“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.

Dr. Avi Baskin and Dr. Katsuto Shinohara were honored for their extraordinary work.

"We are confident that surgery for [testicular seminoma] will be included into treatment guidelines in the near future,” says Sia Daneshmand, MD.

In an episode of Cleveland Clinic’s Cancer Advances podcast, Christopher Weight, MD, center director of Urologic Oncology at Cleveland Clinic, discusses robot-assisted retroperitoneal lymph node dissection.

The program will feature leaders in GU robotic reconstruction and will emphasize novel techniques and innovation in managing complex reconstructive challenges.

The National Cancer Institute has again recognized the UCI Chao Family Comprehensive Cancer Center as one of the nation’s top cancer centers, renewing its “comprehensive” designation

"People with kidney cancer have more effective treatment options than ever before. Not only are they living longer, they are living better,” said David Cella, PhD.

"Because testicular cancer is most often diagnosed in young men and treatments are very successful, the focus is on minimizing the short- and long-term impacts of treatment," says Sprenkle.

Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.

"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.

Although testicular cancer is rare, it is a disease that providers and patients should still be aware of, says Bradley C. Leibovich, MD, FACS.

Stigmas about the disease have negatively impacted the treatment and management of penile cancer, such that patients feel shamed for having the condition and do not seek care, and physicians may not have enough experience with the disease to appropriately provide care. Curtis A. Pettaway, MD, discusses these stigmas further in the following interview.

In a recent interview, Philippe E. Spiess, MD, and Andrea Necchi, MD, shared how they aim to develop an environment that emphasizes education, patient advocacy, and clinical research for rare genitourinary cancers.

“The geographical discrepancies, the social discrepancies, and the impact of these discrepancies in the possibility for the patient to access any type of cure or surgical intervention is critical,” says Andrea Necchi, MD.

“I really foresee this becoming a very critical society in this area for many, many years to come,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.

Benefits include improved quality of life and symptom management.

“The take-home message is that testicular cancer should definitely not be a taboo subject,” says Shawn Dason, MD.

In a recent study, investigators sought to understand the current viewpoints of the general population on testicular cancer and testicular self-examination.

Tian Zhang , MD, discusses the adaptive phase 3 PDIGREE study comparing immunotherapy only versus immunotherapy/TKI regimens in patients with advanced kidney cancer.

“I think the big findings are that men know about testicular cancer, but they may not know a lot and they feel like they could know more,” says Shawn Dason, MD.

“Clearly, we are now in that era of TKIs in addition to checkpoint inhibitors, and so…it makes logical sense from the place we're at [in] the moment in renal cancer treatment with those combinations of treatment,” says Grant Stewart, MD.